Experienced Team
Dr. Norbert Voelkel is the Co-Founder and Chief Medical Officer and is currently the Professor of Medicine and Pathology at Amsterdam University Medical Centers, Amsterdam, The Netherlands. Prior to this, he has held several prominent positions in academia from 1975 to 2014 (University Hospitals, Germany; University of Colorado Health Sciences Center, US; Virginia Commonwealth University School of Medicine, US), founded the University of Colorado COPD research center and has accumulated more than 358 peer-reviewed publications, seven of which are pertinent to this application, 4 non peer reviewed publications, 9 books, and 48 chapters for other books. He has presented at 40 proceedings, and published 53 reviews, perspectives and editorials.
​
Dr. Voelkel’s status as one of the world-renowned, leading experts in pulmonary disease is acknowledged through many honors and awards (American Society for Clinical Investigation (1990), Royal Society of Medicine; London, UK (1992), Endowed Chair, The Hart Family Professor of Emphysema Research, 1999-2007, Association of American Physicians (2001), Top Doctors in America (2001, 2006, 2011, 2012), 25th Annual I. Jerome Flance Lecture, Washington University, St. Louis, April 2002, American Thoracic Society Scientific Achievement Award, May 2002, Estelle Grover Lecture, September 2004, Presidential Lecture, Japanese Respiratory Society Annual Meeting, Chiba, Japan, April 2005, The Copland Lecture, March 2006, Vancouver, BC, The Grover Prize 2006, Endowed Chair, The Raymond Fenton Professor of Pulmonary Research, 2007-2013, Molecular and Cellular Pathobiology of Pulmonary Hypertension 75th Annual Conference of the Mexican Pulmonary Society, Guadalajara, Mexico, March 31st 2016, “From Mechanisms to Disease-a perspective on drug-induced pulmonary hypertension” Am Thoracic Soc. Ann Conference, May 14, San Francisco. American Heart Association Dickinson Richards Memorial Lecture, New Orleans, November 14, 2016).
Mr. Charles Magolske is the Co-Founder and Chief Executive Officer, holds a BS from California Polytechnic University, an MBA from the University of Virginia, and a JD from Loyola University Chicago School of Law. He is a seasoned business executive with many years of experience in fortune 500 and 1,000 USA domiciled companies in global settings. Countries outside the United States he has done business with include Japan, China, India, Australia, Russia, United Kingdom, France, Poland, Germany, Czech Republic, Slovakia, Romania, Italy, Germany, Spain, Portugal, Switzerland, Canada, Mexico, Colombia, Egypt, Saudi Arabia, Guinea and Brazil. Areas of responsibility for Mr. Magolske have included engineering, business development, marketing, acquisitions (including acquisitions of distressed and bankrupt assets), operations management, P&L responsibility, international joint ventures, board positions, and export sales.
​
His last executive position from 2011 to 2015, Mr. Magolske held the position of Vice President of Marketing and Corporate Development for Augusta Resource where he was responsible for marketing and supporting investment transactions and infrastructure development. Since 2015, Mr. Magolske has actively invested in a number of early stage companies in their business development phase, including Applied Therapeutics (Diabetic Cardiomyopathy), Atreca (Cancer), Centrexion (Pain), Alzheon (Alzheimer's Disease), Neumentum (Tylenol analogues and a 505(b)2 reformulation of Ketorolac Toradol), PeerBridge (Heart Monitor), Atea (Anti-viral Therapeutics for Hepatitis and COVID-19), Batiliq (Beta Blockers to treat Glaucoma), and Execia (slow-release formulation of 5-hydroxytryptophan for depression). He is also an active late-stage investor in a number of pre-approval drug companies.
Dr. Erik Eglite, our Chief Business, Regulatory and Compliance Officer, was recently Senior Vice President, General Counsel & Chief Compliance Officer of Aurinia Pharmaceuticals, (Nasdaq: AUPH, TSX: AUP). Prior to joining Aurinia, Erik was Vice President, Chief Compliance Officer and Corporate Counsel for Marathon Pharmaceuticals and Vice President, Chief Compliance Officer and Corporate Counsel for Lundbeck Pharmaceuticals. While at Lundbeck, Erik was Counsel to both Lundbeck/Takeda Pharmaceuticals Partnership, and Lundbeck/Otsuka Pharmaceuticals Partnership. Prior to that, he was Vice President, Chief Compliance Officer and Corporate Counsel for Ovation Pharmaceuticals and Global Chief Compliance Officer and Corporate Counsel for Aspreva Pharmaceuticals (Nasdaq: ADVFN, TSX: ASV), which was acquired by Vifor Pharmaceuticals. Erik has been involved with the development, regulatory approval, launch and commercialization of 16 drugs and drug programs, including Lupkynis™, Abilify®, CellCept®, Onfi®, Northera®, NeoProfen®, Panhematin®, ATryn®, Trintellix®, Sabril®, Xenazine®, Rexulti®, Brintellix® and Emflaza®. He is a nationally recognized and frequent speaker on pharmaceutical law. Before entering the pharmaceutical industry, Erik worked as Assistant General Counsel for the Department of Human Services and as a medical malpractice, product liability defense litigation and intellectual property, patent attorney for Querry & Harrow in Chicago, Illinois. He is a licensed podiatric physician and surgeon and is registered to practice before the United States Patent and Trademark Office, the United States Court of Appeals for the Federal Circuit, the United States Court of Appeals for the District of Columbia Circuit, the United States Seventh Circuit Court of Appeals and the United States District Court for the Northern District of Illinois. Erik is an Advisory Board Member for the Harper Cancer Research Institute at the University of Notre Dame.
Erik has a M.B.A. from the University of Notre Dame and a M.S. in F.D.A. Regulatory Legal Compliance & Clinical Research from Northwestern University. He also holds a B.S. in Biology, a B.A. in History, M.Sc. in Chemistry, and a J.D. from Loyola University of Chicago. He graduated from Des Moines University Iowa Medical School (2019 Alumni of the Year) with a Doctorate in Podiatric Medicine and Surgery, D.P.M., after which he completed his residency training at Michigan Health Medical Center Hospital. He also completed his medical/surgical externships at the University of Chicago, Department of Surgery, Division of Vascular Surgery; Great Lakes Naval Hospital Department of Podiatric Surgery; and Northwestern University Columbus Cabrini Hospital, Department of Orthopedic/Podiatric Surgery. He has a graduate certificate in Pharmaceutical & Medical Device Law from Seton Hall School of Law, an Executive Certificate in Corporate Governance from Northwestern University Kellogg School of Management and an Executive Certificate in Business Administration from the University of Notre Dame.
​
David Doyle - General Counsel. Advises businesses and investors in manufacturing, technology and health care sectors. He has a Masters in Health Care Law and is the former Chair of the Institute of Illinois Business Laws and the Business and Securities Law Section Council of the Illinois State Bar Association.
Joana Pinto, Ph.D. – Vice President of Innovation and Development and Senior Scientist, holds a Masters in Pharmaceutical Sciences from the University of Lisbon and has a PhD from the University of Graz, Austria in the area of pharmaceutical technology. Joana has worked for 8+ years in the interface between industry and academy in various innovative R&D projects for the pharmaceutical industry, particularly in the area of respiratory diseases. She has authored 20+ peer-reviewed research/review papers and a book chapter. Joana has just completed her MBA at the Vienna University of Economics and Business